Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Brain Imaging01:14

Brain Imaging

Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans),  magnetic resonance imaging (MRI),  functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Imaging Studies IV: Magnetic Resonance Imaging01:27

Imaging Studies IV: Magnetic Resonance Imaging

Introduction:Magnetic Resonance Imaging, or MRI, can include a specialized imaging technique of the urinary system known as Magnetic Resonance Urography (MRU). This radiation-free technique uses strong magnetic fields and radio waves to produce detailed images with the help of a computer. MRU is particularly effective for visualizing fluid-filled structures like the kidneys, ureters, and bladder.Applications of MRI in the Genitourinary SystemKidneys and Ureters: MRI detects tumors, cysts,...
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterising high-resolution dynamics of inflammatory and SCFA responses to food consumption in healthy men: A pilot biomarker discovery study.

Cytokine·2025
Same author

Agreement between early-phase amyloid-PET and pulsed arterial spin labeling in a memory clinic cohort.

Journal of molecular medicine (Berlin, Germany)·2025
Same author

Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators.

The journal of prevention of Alzheimer's disease·2024
Same author

Resting-state functional connectivity abnormalities in subjective cognitive decline: A 7T MRI study.

Neurobiology of aging·2024
Same author

Musical and psychomotor interventions for cognitive, sensorimotor, and cerebral decline in patients with Mild Cognitive Impairment (COPE): a study protocol for a multicentric randomized controlled study.

BMC geriatrics·2023
Same author

Facile synthesis of 3D flower-like Pt nanostructures on polypyrrole nanowire matrix for enhanced methanol oxidation.

RSC advances·2022

Related Experiment Video

Updated: Jul 13, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
08:33

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Neuroimaging outcomes for clinical trials.

G B Frisoni1, A Caroli

  • 1G.B. Frisoni, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.

The Journal of Nutrition, Health & Aging
|July 27, 2007
PubMed
Summary

Imaging markers offer a more sensitive and direct way to measure Alzheimer's disease progression in clinical trials. This approach can reduce trial size and provide biological insights beyond symptom delay.

Area of Science:

  • Neuroscience
  • Medical Imaging
  • Pharmacology

Background:

  • Alzheimer's Disease (AD) drug development faces challenges with traditional outcome measures like rating scales due to variability and slow progression.
  • Current clinical trials often require large patient cohorts, increasing costs and time.
  • Assessing the biological impact of AD therapeutics beyond symptomatic relief is crucial.

Purpose of the Study:

  • To review the utility of imaging markers as outcome measures in Alzheimer's Disease clinical trials.
  • To highlight the advantages of imaging markers over traditional scales for assessing disease modification.

Main Methods:

  • Review of prospective studies utilizing imaging markers (structural, functional, amyloid) to track disease progression over time.
  • Focus on techniques applied in studies investigating changes in imaging markers.

More Related Videos

In vivo Positron Emission Tomography to Reveal Activity Patterns Induced by Deep Brain Stimulation in Rats
09:36

In vivo Positron Emission Tomography to Reveal Activity Patterns Induced by Deep Brain Stimulation in Rats

Published on: March 23, 2022

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
13:12

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping

Published on: August 12, 2019

Related Experiment Videos

Last Updated: Jul 13, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
08:33

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

In vivo Positron Emission Tomography to Reveal Activity Patterns Induced by Deep Brain Stimulation in Rats
09:36

In vivo Positron Emission Tomography to Reveal Activity Patterns Induced by Deep Brain Stimulation in Rats

Published on: March 23, 2022

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
13:12

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping

Published on: August 12, 2019

Main Results:

  • Imaging markers demonstrate sensitivity to disease progression, offering a direct measure of biological changes.
  • Utilizing imaging markers can significantly decrease the number of subjects required per treatment arm in clinical trials.
  • Imaging provides a direct assessment of disease modification induced by therapeutic agents.

Conclusions:

  • Imaging markers represent a significant advancement for Alzheimer's Disease clinical trials.
  • These markers enhance the ability to measure drug efficacy and disease modification.
  • The adoption of imaging markers promises more efficient and informative clinical trial designs.